Dapagliflozin Efficacy and Action in NASH

Inclusion Criteria: * Men or women aged≥18 years; * Non-alcoholic steatohepatitis as determined by liver biopsies within 6 months; * Patients with T2DM at screening had to have stable glycaemic control (HbA1c \<9.5%) . Exclusion Criteria: 1. Significant alcohol consumption in the past six months (Consumed more than 20 g/day for women or 30 g/day for men); 2. A history of alcoholic liver disease, chronic viral hepatitis, drug-induced hepatitis, autoimmune hepatitis, cirrhosis, and liver cancer; 3. Obstructive biliary disease; 4. Having any medical condition that would affect metabolism (i.e. Cushing syndrome, known hyperthyroidism or hypothyroidism); 5. Poor glucose control (defined as HbA1C≤ 9.5% within 3 months) if diagnosed with T2DM, or taking any antidiabetic medication that would affect metabolism or weight loss (i.e. TZD, GLP-1, DPP-4i or initially using insulin in the past 3 months); 6. Taking any medication (i.e. cortisol, methotrexate)that would affect steatohepatitis for more than two weeks in the past year; 7. Chronic kidney disease or severe impaired renal function (serum creatinine≥ 2.0mg/dl); 8. Serum alanine aminotransferase (ALT) greater than 300U/L 9. A history of Type 1 diabetes; 10. A history of bladder cancer; 11. Women who are pregnant or plan to become pregnant; 12. Serious medical disease with likely life expectancy less than 5 years; 13. Patients who cannot be followed for 24 months (due to a health situation or migration); 14. Participation in other clinical trial in the 30 days before randomization; 15. Patients who are unwilling or unable to give informed consent.